Antibiotic in Biological Technology

Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

... a clinical recurrence following cessation of antibiotic administration. Primary risk factors for CDI include broad-spectrum antibiotic use, advanced age (over 65), emerging ... formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical ...

Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer

... lead product, MP-376. MP-376 is an inhaled antibiotic which is being developed for use as a maintenance ... new therapies to combat the growing issue of antibiotic resistance. The company's internal development ... molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's most advanced product ...

Neogen Reports Record Third Quarter

... year-to-date growth to 15%. Sales of dairy antibiotic tests declined in the third quarter due ... final hurdle to sell its new BetaStar(R) US dairy antibiotic test by receiving an approval from the FDA and ... test opens up the domestic test market for dairy antibiotic residues. Neogen's increased focus on ...

Neogen's BetaStar(R) US Dairy Antibiotic Test Approved by FDA/NCIMS

... BetaStar US is one of the fastest dairy antibiotic tests available, and can be used on the farm, ... responsible for approximately 95% of all milk antibiotic contamination. BetaStar US complements the ... which also includes: TetraStar(R), a dairy antibiotic test for tetracyclines; rapid milk allergen tests ...

AdvanDx's PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections

... the administration of inadequate or inappropriate antibiotic treatment as E. faecium is often resistant to ... that enables clinicians to select effective antibiotic therapy sooner for patients afflicted with ... bloodstream infections receive effective antibiotic therapy as early as possible and help save close ...

Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus

... new tool to aid in selecting the most effective antibiotic therapy to improve patient management. "The ... addition, the GeneXpert System supports informed antibiotic choices whereby prescribing antibiotics of last ... the chances of microbes further developing antibiotic resistance." Community Acquired Infections in ...

Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States

... The antibiotic surgical product may reduce incidence of surgical ... be the first and only biodegradable, leave-behind antibiotic surgical sponge used as an adjunct (add-on) ... gentamicin, designed to deliver the antibiotic directly to the target tissue while maintaining ...

Arpida's iclaprim MAA Accepted for Review by EMEA

... Tissue Infections (cSSTI). Iclaprim is a hospital antibiotic drug candidate with potent bactericidal (killing) ... pneumonia (HCAP). Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ... infection and nasal carriage. Apart from the antibiotic programmes, Arpida has an innovative antifungal ...

U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis

... empiric therapy -- prescribing an antibiotic treatment immediately before an accurate and firm ... that antibiotic resistance stemming from antibiotic misuse is a primary concern as it may have an ... dramatic improvement in patient care and improve antibiotic stewardship. About bioMerieux Advancing ...

FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia

... pneumonia." DORIBAX is an intravenous (IV) antibiotic for hospital use, and belongs to a class of ... all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since ... If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to ...

Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007

... of Inpatient Therapy per Patient Treated with an antibiotic for MRSA Decreased by 10 Percent, According to ... finds that the number of patients treated with an antibiotic associated with a positive culture for MRSA ... The newly released edition of The U.S. Hospital antibiotic Market Guide finds that the most common ...

GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections

... of Mpex Pharmaceuticals. "The critical role of antibiotic efflux has been well recognized in bacterial ... and we believe that a number of these antibiotic opportunities could benefit from the addition of ... enable progressive development of GSK's novel antibiotic pipeline. Mpex has a first rate entrepreneurial ...

Dragon Pharma announces 2007 full year financial results

... sold its EPO business to fully focus on its core antibiotic business that has showed significant growth ... for Clavulanic Acid. - With a more focused antibiotic product portfolio and effective marketing ... to meet rising customer demand. - Two new antibiotic products, Ceftazidime and Cefalexin, have been ...

Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients

... for inhalation. ARIKACE is a form of the antibiotic amikacin, which is enclosed in nanocapsules of ... from clearing infections even under aggressive antibiotic treatment. It is not practical to observe biofilm ... neutrally charged ARIKACE liposomes facilitated antibiotic passage through the patient mucus layer and ...

Arpida Announces Full Year 2007 Financial Results

... of 'first-in-man' studies with AR-709 - Novel antibiotic AR-2474 achieves preclinical proof of concept - ... own drug discovery efforts. It is a bactericidal antibiotic that is being developed for the treatment of ... is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring ...

Dragon announces new product launch; increase in annual production output capacity

... is a first-generation cephalosporin antibiotic but its chemical composition makes it effective ... Pharmaceutical Group, the largest producer of antibiotic drugs in China. "We are very pleased to have ... with his depth of knowledge in the Chinese antibiotic industry, will be invaluable to Dragon and will ...

Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis

... administration. Levofloxacin is a powerful antibiotic that has been widely used in a variety ... new therapies to combat the growing issue of antibiotic resistance. The company's internal development ... molecular mechanisms in bacteria responsible for antibiotic resistance. Mpex's lead product candidate, ...

Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim

... is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring ... patient comfort. Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ... infection and nasal carriage. Apart from the antibiotic programmes, Arpida has an innovative antifungal ...

Neogen Launches Quickest Test Available for Tetracyclines in Milk

... Neogen's new TetraStar(R) dairy antibiotic test for tetracyclines complements the company's ... are more widely used. The worldwide market for antibiotic testing of milk has been estimated to exceed $60 ... to dairy processing plants is tested for antibiotic residues. In addition to its growing line of ...

Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis

... is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring ... patient comfort. Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ... infection and nasal carriage. Apart from the antibiotic programmes, Arpida has an innovative antifungal ...

Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim

... is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring ... patient comfort. Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ... infection and nasal carriage. Apart from the antibiotic programmes, Arpida has an innovative antifungal ...

Arpida-Supported CME Symposium Available Online

... 32 posters: 19 on the late-stage investigational antibiotic iclaprim and a total of 13 on AR-709 and ... iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital ... comfort. Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ...

First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP

... iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital ... comfort. Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ... infection and nasal carriage. Apart from the antibiotic programmes, Arpida has an innovative antifungal ...

Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim

... iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital ... patient comfort. Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ... infection and nasal carriage. Apart from the antibiotic programmes, Arpida has an innovative antifungal ...

Schering-Plough Completes Acquisition of Organon BioSciences

... such as COBACTAN, a broad-spectrum antibiotic for livestock species and horses; and specialty ... with products such as NUFLOR, a broad-spectrum antibiotic for cattle, swine and fish; OTOMAX, a canine ear ointment; RESFLOR, a combination antibiotic and anti-inflammatory for bovine respiratory ...

Advanced Life Sciences Announces Third Quarter 2007 Financial Results

... the area of respiratory tract infections and antibiotic therapies. Business Outlook for the Fourth ... cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the ... build upon the growing market opportunity in the antibiotic marketplace and address the critical need for ...

Arpida Presents Data on Iclaprim at Scientific Congress in Germany

... posters on its late-stage investigational antibiotic iclaprim at the 9th annual congress for ... iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital ... patient comfort. Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower ...

Arpida Presents Preclinical Data on AR-2474 at ICAAC

... several preclinical studies on its novel topical antibiotic AR-2474 at the 47th annual Interscience ... is intravenous iclaprim, a broad-spectrum antibiotic that targets severe infections requiring ... infection and nasal carriage. Apart from the antibiotic programmes, Arpida has an innovative antifungal ...

Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC

... Iclaprim is a novel late stage investigational antibiotic which exhibits potent activity against ... community and hospital infections. Iclaprims Post antibiotic Effect (PAE) was comparable to other agents in ... is intravenous iclaprim, a broad-spectrum antibiotic that targets severe infections requiring ...

Mpex Pharmaceuticals Names Dr. Jeffery Loutit as Chief Medical Officer

... on developing products to overcome issues of antibiotic resistance, today announced the appointment of ... area of efflux pump biology, a primary source of antibiotic resistance in gram negative organisms. The ... of novel approaches to overcoming gram-negative antibiotic resistance." About Mpex Pharmaceuticals: Mpex ...

Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting

... lead antibiotic candidate, oritavancin, and its antibiotic drug discovery platform at the upcoming 47th ... of oritavancin, Targanta's investigational antibiotic for the treatment of gram-positive infections, ... A-50 Poster McKay In vitro Post antibiotic ...

Arpida Interim Results for six Months to 30 June 2007

... confirm iclaprims safety profile Novel antibiotic AR-2474 achieves preclinical proof of concept ... against many of the current drugs, I feel these antibiotic programmes are aimed at significant existing or ... own drug discovery efforts. It is a bactericidal antibiotic that is being developed for the treatment of ...

Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results

... under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of ...

Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference

... under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of ...

Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria

... ARIKACE(TM) ARIKACE is a sustained-release formulation of the antibiotic amikacin, which encloses the drug in nanocapsules of lipid called ... of chronic lung diseases. The company's major focus is on developing antibiotic therapy delivered via proprietary advanced pulmonary liposome technology ...

Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors

... on the discovery and development of novel antibiotics for the treatment of antibiotic resistant infections, announced today that Russell Greig, Ph.D., of SR One ... allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded ...

Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections

... wound the product releases gentamicin, a broad-spectrum, aminoglycoside antibiotic with a concentration-dependent mechanism of action, for local action at ... One study is investigating the product as an adjunct to systemic antibiotic therapy for treating moderately infected ulcers compared to systemic ...

Optimer Pharmaceuticals to Present at June 2009 Investor Conferences

... under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of ...

Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results

... under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of ...

Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board

... at the Upjohn Company for the development of linezolid, the sole marketed antibiotic in the oxazolidinone class. "I look forward to working closely with ... candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial ...